research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
Search
for
Sort by
Research
450-480 / 1000+ results 
research TREMendous Macrophages Inhibit Hair Growth
Certain immune cells in the skin can stop hair from growing.
research The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
Tofacitinib may be safe and effective for treating certain skin conditions in children.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review
TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies
Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.
research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK /STAT inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
research Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
An elderly Chinese man lost all his hair after taking a new heart medication.
research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
Baricitinib is effective and safe for treating severe alopecia areata.
research Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights
Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
research Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research Turning JAK STATic, a peek into the future of dermatology therapeutics
JAK inhibitors show promise for treating skin diseases effectively and safely.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Application of Baricitinib in Dermatology
Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
research Artepillin C and Other Herbal PAK1-blockers: Effects on Hair Cell Proliferation and Related PAK1-dependent Biological Function in Cell Culture
Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
research An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research Tofacitinib therapy for children with severe alopecia areata
Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
research Cardiodermatology: the heart of the connection between the skin and cardiovascular disease
Skin conditions can signal heart issues, highlighting the need for integrated care.
research Ottawa, Ontario, Canada, February 13–16, 2013
The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.